【个人简介】

1971年生，女，博士，肿瘤内科主任医师，广州医科大学肿瘤学教授，硕士生导师，广州医科大学博士后工作站导师，广医医院肿瘤中心、呼吸病研究所肺癌专业组奠基人，1995年毕业于广州医学院，从事肿瘤内科工作28年，获血液学硕士学位，肿瘤学博士学位。

【研究方向】

肿瘤易感基因、肺癌的个体化精准治疗

【科研项目】

主持国家卫生部重大科技专项基金课题、广东省科技厅临床科研专项以及吴阶平医学基金会资助基金等多项国家级及省部级科研项目

【代表性论文及著作】

1， Zhang et al.- 2025 -Association between EGFR mutation, types and incidence of brain in postoperative patients with stage I-III NSCLC第一作者

2， Zhang et al. - 2023 - Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lu-annotated，第一作者

3， Chen et al. - 2023 - EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Pro-annotated

4， Zhang et al. - 2022 - Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer-annotated

5， Li et al. - 2022 - KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations recei-annotated，通讯作者

6， Chen et al. - 2022 - First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal gro-annotated，通讯作者

7， DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.2022

8， Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian.2022

9， Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.

10， Ke et al. - 2021 - Novel PHOX2B germline mutation in childhood medulloblastoma a case report-annotated，通讯作者

11， Liu et al. - 2021 - Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers-annotated

12， A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma. 2021

13， Clonal architecture of EGFR mutation predicts the efficacy of EGFR-tyrosine kinase inhibitors in advanced NSCLC A pro-annotated，（2021），第一作者

14， Development and validation of a model to predict tyrosine kinase inhibitor-sensitive EGFR mutations of non-small cell lung cancer based on multi-institutional data. 2020

15， ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non‑small cell lung cancer，2020

16， Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.

17， Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing，（2018）

18， RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial，（2017）

19， An expression signature model to predict lung adenocarcinoma-specific survival 2018

20， The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis 2017

21， IRE1a-TRAF2-ASK1 pathway is involved in CSTMP-induced apoptosis and ER stress in human non-small cell lung cancer A549 cells. Biomedicine & Pharmacotherapy 82，(第一作者)，(2016)

22， AP与TP方案在EGFR－TKI耐药的非小细胞肺癌患者中的疗较比较 张洁霞 ，蔡迪 ，占杨清 ，周承志 ，秦茵茵， 欧阳铭 ，李时悦*广州医学院学报，2015

23， 中西医结合与纯西医治疗中晚期非小细胞性肺癌的长期预后比较研究 张洁霞， 蔡迪 ，柳元斌 ， 潘素滢. 广东医学，2014

24， Fatal interstitial lung disease associated with icotinib. A case report and a review of the literature.Journal of thoracic disease，2014

25， 中国非小细胞肺癌患者EGFR和KRAS基因的突变情况和临床特征分析，张洁霞, 何建行, 李时悦 . 临床肿瘤学杂志，2014

26， 非小细胞肺癌脑转移的预后因素分析.张洁霞，蔡迪，欧阳铭，周承志.临床肺科杂志，2014

27， 非小细胞肺癌脑转移厄洛替尼与吉非替尼治疗临床比较，2015

【所获荣誉和奖励】

1.2017年好大夫平台呼吸内科全国第二名，连续9年“年度好大夫”